Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Male or female patient who had endothelial keratoplasty procedure within the past 1 to 7 weeks~* Patient is able and willing to administer eye drops~* Patient is able to comprehend and has signed the Informed Consent form.~* Patient is likely to complete the one-year course of the study~Exclusion Criteria:~* A history of a previous rejection episode in the study eye~* A patient exhibiting intraocular inflammation~* A patient with a known sensitivity to any of the ingredients in the study medications~* A patient who has a condition (i.e., UNCONTROLLED systemic disease) or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study~* A patient with abnormal eyelid function.~* A patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis.~* Presence of any ocular disease that would interfere with the evaluation of the study treatment. However, patients with a history of cystoid macular edema, age-related macular degeneration, controlled glaucoma, corneal neovascularization, and other non-interfering comorbidities may be enrolled.~* A patient with a history of non-compliance with using prescribed medication.~* A patient who is concurrently involved in or participated in another randomized clinical trial within 30 days prior to enrollment in this study.~* Patients who are pregnant or planning to become pregnant within the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loteprednol (Type: ACTIVE_COMPARATOR): Loteprednol etabonate 0.5% gel applied topically 4 times daily for 2 months, 3 times daily for 1 month, twice daily for one month and once daily for 7 months
- Prednisolone acetate (Type: ACTIVE_COMPARATOR): Prednisolone acetate 1% ophthalmic solution applied 4 times daily for two months, 3 times daily for one month, twice daily for one month, and once daily for 7 months

Based on this trial design, predict the completion outcome and termination type (if applicable).